anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PCT No. PCT/FR90/00054 Sec. 371 Date Sep. 3, 1991 Sec. 102(e) Date Sep. 3, 1991 PCT Filed Jan. 25, 1990 PCT Pub. No. WO90/08775 PCT Pub. Date Aug. 9, 1990.Novel polypeptides having a (beta)-adrenergic receptor activity containing the sequence of 402 amino acids, or a fragment of this sequence, said fragment being such that, in particular, either it nonetheless includes the sites contained in said sequence and whose presence is necessary so that, when the fragment is exposed to the surface of a cell, it is capable of participating in the activation of the cyclase adenylate in the presence of an agonist, or it is likely to be recognized by antibodies which also recognize the above succession of 402 amino acids, but fail to recognize the (beta)1 adrenergic receptor and the (beta)2 adrenergic receptor. These polypeptides are useful for screening drugs which act on said polypeptides and for treating obesity, fat diabetes and hyperlipidemias.
PURPOSE: A composition containing Asparagus cochinchinensis is provided to ensure cytotoxicity to cancer cells and to suppress cancer metastasis. CONSTITUTION: A composition for suppressing cancer metastasis contains Asparagus cochinchinensis extract as an active ingredient. The Asparagus cochinchinensis extract is isolated using water, low alcohol of C1-C4, or mixture solvent thereof. The low alcohol is methanol or ethanol. The composition additionally contains organic solvent fraction of Asparagus cochinchinensis extract as an active ingredient. The organic solvent is n-hexane, methylene chloride, ethyl acetate, or n-butanol. A health food for preventing and treating cancer contains Asparagus cochinchinensis extract or fraction thereof as an active ingredient.
The heart relies on various defense mechanisms, including metabolic plasticity, to maintain its normal structure and function under high-altitude hypoxia. Pioglitazone, a peroxisome proliferator-activated receptor γ (PPARγ), sensitizes insulin, which in turn regulates blood glucose levels. However, its preventive effects against hypoxia-induced cardiac dysfunction at high altitudes have not been reported. In this study, pioglitazone effectively prevented cardiac dysfunction in hypoxic mice for 4 weeks, independent of its effects on insulin sensitivity. In vitro experiments demonstrated that pioglitazone enhanced the contractility of primary cardiomyocytes and reduced the risk of QT interval prolongation under hypoxic conditions. Additionally, pioglitazone promoted cardiac glucose metabolic reprogramming by increasing glycolytic capacity; enhancing glucose oxidation, electron transfer, and oxidative phosphorylation processes; and reducing mitochondrial reactive ROS production, which ultimately maintained mitochondrial membrane potential and ATP production in cardiomyocytes under hypoxic conditions. Notably, as a PPARγ agonist, pioglitazone promoted hypoxia-inducible factor 1α (HIF-1α) expression in hypoxic myocardium. Moreover, KC7F2, a HIF-1α inhibitor, disrupted the reprogramming of cardiac glucose metabolism and reduced cardiac function in pioglitazone-treated mice under hypoxic conditions. In conclusion, pioglitazone effectively prevented high-altitude hypoxia-induced cardiac dysfunction by reprogramming cardiac glucose metabolism.
The potential relationship between the gut microbiota and prostate cancer, possibly influenced by immune cells, remains unclear. This study employed the mediation Mendelian randomization (MR) technique to investigate the causal link between the gut microbiota, immune cells, and prostate cancer. Data on immune cell activity were sourced from Valeria Orrù's research, whereas the genome-wide association study outcome dataset was obtained from the Integrative Epidemiology Unit database. The bidirectional MR analysis utilized 5 different methods: inverse variance weighted (IVW), weighted median, MR-Egger regression, weighted mode, and simple mode. In addition, the mediating effect of immune cells on the gut microbiota and prostate cancer was explored using mediation analysis. Eighty-three single nucleotide polymorphisms associated with prostate cancer were screened as instrumental variables. In a positive MR analysis with gut microbiota as the exposure factor, IVW showed an association between 8 gut microbiota and prostate cancer. Additionally, 9 types of immune cells have been found to be associated with prostate cancer using methods such as IVW. MR analysis of the gut microbiota on immune cells (beta1) revealed a negative correlation between Bifidobacterium and CD39+ T regulatory cells (Tregs; odds ratio [OR] = 0.785, 95% confidence interval [CI] = 0.627-0.983, P = .03). Furthermore, MR analysis of immune cells in prostate cancer disease (beta2) showed that CD39+Tregs are a risk factor for prostate cancer (OR = 1.215, 95% CI = 1.027-1.354, P = .04). Moreover, MR analysis of gut microbiota in prostate cancer (total effect) indicated that Bifidobacterium is a protective factor for prostate cancer (OR = 0.905, 95% CI = 0.822-0.977, P = .04). The sensitivity analysis verified the robustness of the above results. Mediation analysis demonstrated that CD39+Tregs partially mediate the causal relationship between Bifidobacterium and prostate cancer. This study demonstrates that Bifidobacterium inhibits prostate cancer progression through CD39+Tregs as mediators, providing new ideas and approaches for the treatment and prevention of prostate cancer.
If assigned to the immediate BT condition, patients will be asked to make about 24 visits to our clinics at MGH, including an initial assessment, 12 therapy visits over 12 weeks, and 1 booster session (Week 16). Patients will be asked to come to the clinic for assessments during weeks 4 and 6 and after the treatment (week 12), as well as 1 follow-up visit (week 24). Additionally, patients will participate in 6 MRI scanning sessions at the Charlestown Navy Yard.
Di-hexyl phthalate (2-ethylhexyl) (DEHP) has been confirmed to cause female reproductive toxicity in humans and model animals by affecting the survival of ovarian granulosa cells (GCs), but the interrelationships between DEHP's on autophagy, apoptosis, and inflammation in GCs are not clear. Our previous study demonstrated that DEHP exposure resulted in the disturbance of intestinal flora associated with serum LPS release, which in turn led to impaired ovarian function. LPS has also been shown to determine cell fate by modulating cellular autophagy, apoptosis, and inflammation. Therefore, this study investigated the role and link between LPS and autophagy, apoptosis, and inflammation of GCs in DEHP-induced ovarian injury. Here, we constructed an in vivo injury model by continuous gavage of 0-1500 mg/kg of DEHP in female mice for 30 days and an in vitro injury model by treatment of human ovarian granulosa cells (KGN) cells with mono-2- ethylhexyl ester (MEHP, an active metabolite of DEHP in vivo). In addition, the expression of relevant pathway molecules was detected by immunohistochemistry, immunofluorescence, qRT-PCR, and Western blotting after the addition of the autophagy inhibitor 3-methyladenine (3-MA), the apoptosis inhibitor Z-VAD- FMK and the NF-κB inhibitor BAY11-7082. The current study found that autophagy and apoptosis were significantly activated in GCs of DEHP-induced atretic follicles in vivo and found that MEHP-induced KGN cells autophagy and apoptosis were independent and potentially cytotoxic of each other in vitro. Further studies confirmed that DEHP exposure resulted in LPS release from the intestinal tract and entering the ovary, thereby participating in DEHP-induced inflammation of GCs. In addition, we found that exogenous LPS synergized with MEHP could activate the NF-κB signaling pathway to induce inflammation and apoptosis of GCs in a relatively prolonged exposure condition. Meanwhile, inhibition of inflammatory activation could rescue apoptosis and estrogen secretion function of GCs induced by MEHP combined with LPS. These results indicated that the increased LPS influenced by DEHP might cooperate with MEHP to induce inflammatory apoptosis of GCs, an important cause of ovarian injury in mice.
This study is an open-label, single-center, randomized, comparative phase IV clinical trial. The purpose of this study is to evaluate the safety andimmunogenicity of concomitant administration of EV71 vaccine manufactured by Sinovac (Beijing) Vaccine Technology Co., Ltd. with measles mumps, and rubella combined live attenuated vaccine/ encephalitis live attenuated vaccine. 360 healthy infants of 8 months old as participants are randomly assigned into three experimental groups in the ratio 1:1:1. The group I receive EV71 Vaccine (first dose)\&measles mumps, and rubella combined live attenuated vaccine on day 0 and EV71 vaccine (second dose)\&encephalitis live attenuated vaccine on day 30. The group II receive measles mumps, and rubella combined live attenuated vaccine on day 0 and encephalitis live attenuated vaccine on day 30. The group III receive the first and second dose of EV71 Vaccine on day 0 and day 30 respectively.
During the eight weeks, children in the coordinative exercise intervention group participated in sessions twice a week, each lasting 20 minutes. The foundational movement patterns tailored to the specific purpose were organized in a game format suitable for preschool-aged children. These foundational movement patterns comprise open-ended tasks progressing from simple to complex, with motor planning as a prerequisite. As the exercise intervention was game-based, the sessions were maintained as a fun, active, and social learning environment for the children.
The aim of this study is to evaluate and compare the pulp response of young permanent first molars after apexogenesis procedure, using melatonin versus MTA clinically and radiographically. This study will be performed on 45 young permanent first molars that will be divided equally into three groups according to the material used following apexogenesis; GroupI: MTA, GroupII: Melatonin and GroupIII: MTA and Melatonin. apexogenesis procedures will be carried out in children aged 6 to 8 years old. This will be followed by placement of MTA or/and Melatonin material as a sub base in the pulp chamber according to the group. Then, placement of a conventional glass ionomer cement (FUGI IX) as a permanent restoration will be conducted. Then, an immediate postoperative periapical digital x-ray film will be taken for the patients. The patient follow-up will be assigned 1,3,6,9 and 12 months after treatment.
Cyclosporine is the active ingredient of cyclosporine capsules (modified). Hypertension is a common side effect of cyclosporine therapy which may persist (see ADVERSE REACTIONS and DOSAGE AND ADMINISTRATION for monitoring recommendations). Mild or moderate hypertension is encountered more frequently than severe hypertension and the incidence decreases over time. In recipients of kidney, liver, and heart allografts treated with cyclosporine, antihypertensive therapy may be required (see Special Monitoring of Rheumatoid Arthritis and Psoriasis Patients). However, since cyclosporine may cause hyperkalemia, potassium-sparing diuretics should not be used. While calcium antagonists can be effective agents in treating cyclosporine-associated hypertension, they can interfere with cyclosporine metabolism (see Drug Interactions).
PURPOSE:To provide a vasographic agent containing finely divided emulsion particles, having excellent stability, storable for a long period without causing the agglomeration of the particles, and applicable safely, by adding alpha-tocopherol or its ester to a brominated perfluorocarbon emulsion. CONSTITUTION:The vasographic agent is obtained by using a brominated perfluorocarbon containing one or two bromine atoms in one molecule as a main component, mixing the component with an emulsifier (e.g. a phospholipid, a nonionic surfactant having a molecular weight of 2,000-20,000) and an emulsion assistant (e.g. 8-22C fatty acid), added with alpha-tocopherol or its ester as the stabilizer of the emulsion particles, and homogeneously emulsifying the mixture. Preferably, the vasographic agent is added to a prescribed amount of a medium such as physiological saline water, etc. at ratios of 5-50% (W/V) bromonated perfluorocarbon, 2-6% emulsifier, 0.001-0.1% emulsion assistant and 0.004- 0.2% stabilizer, and emulsified homogeneously to attain an average particle diameter of 0.05-0.25mu.
PROBLEM TO BE SOLVED: To provide a modified VII factor polypeptide and a use method thereof.SOLUTION: This invention provides a modified FVII polypeptide wherein the modified FVII polypeptide shows increased tissue factor (TF)-dependent coagulation activity compared to an unmodified FVII polypeptide, and an active fragment thereof. This invention provides a nucleic acid molecule containing a nucleotide sequence encoding the modified FVII polypeptide. This invention provides a vector containing the nucleic acid molecule. This invention provides a cell containing the vector. This invention provides a method of producing a modified FVII polypeptide which includes a step of culturing the cell. This invention provides a pharmaceutical composition containing, in a pharmaceutically acceptable carrier, a therapeutically effective concentration or amount of the modified FVII polypeptide, or the nucleic acid molecule or the vector or the cell.
Cervical cancer is the fourth most common cancer in women worldwide and is caused by persistent infection with high-risk types of human papillomavirus (HPV). HPV viral load, the amount of HPV DNA in a sample, has been suggested to correlate with cervical disease severity, and with clinical outcome of cervical cancer. In this systematic review, we searched three databases (EMBASE, PubMed, Web of Science) to examine the current evidence on the association between HPV viral load in cervical samples and disease severity, as well as clinical outcome. After exclusion of articles not on HPV, cervical cancer, or containing clinical outcomes, 85 original studies involving 173 746 women were included. The vast majority (73/85 = 85.9%) reported that a higher viral load was correlated with higher disease severity or worse clinical outcome. Several studies reported either no correlation (3/85 = 3.5%), or the opposite correlation (9/85 = 10.6%); possible reasons being different categorization of HPV viral load levels, or the use of specific sampling methods. Despite variations in study design and populations, the above findings suggest that HPV viral load is correlated to clinical outcome, and may become an important biomarker for treatment selection and response monitoring for cervical cancer.
The alveolar ridge resorbs and collapses following tooth removal which continues to be a major concern for practitioners. Many researchers concluded that buccal aspect of the ridge is more prone to resorption, as it is primarily supplied by the periodontal tissues and ligments of the tooth. Therefore, extraction of the hopeless tooth, may be a reason for buccal cortical plate resorbing at a faster rate than the palatal plate leading to its total degradation. This may lead to dimensional changes in the human ridge and the aesthetic area is highly affected by this process. Several techniques in the litreture were proposed to solve the problem of thin buccal bone resorption with or without immediate implantation in the aesthetic area. Some of these techniques are the guided bone and soft tissue regenraton and bone augmentation but proved to be slight aggressive with high morbidity rate. Recently, several papers were published concerning the socket shield technique explaining how to maintain the ridge width and height. Socket shield technique that was first introduced in 2010 aids at retaining the buccal fragment of root in place and intact thus placing the implant behind the lingual aspect of that fragment so that the periodontal ligments and tissues preserve its vitality and aids in preventing the collapsing of the buccal bone. This would help in improving aesthetics especially during immediate implant placment in the anterior maxillary region.
The study is a randomized, controlled study. 52 participants will be included to study who apply to Dokuz Eylül University Faculty of Medicine, Department of Physical Medicine and Rehabilitation Clinic with the complaint of hip and back pain, aged between 18-60 years. Participants have diagnosed as Sacroiliac Joint Dysfunction according to The International Association for the Study of Pain (IASP) diagnostic criteria. These participants will be divided into two groups randomly (Treatment group n:26, control group n:26). Because the therapeutic effect may be seen with unsealed banding in Kinesio taping and the placebo effect may not be evaluated, After the last evaluation, participants in both groups will be given the necessary treatment and since there is no study on this subject in the literature, no treatment was given to the control group due to the fact that the actual effect of banding was desired. The treated group received Kinesio taping 3 times at 5-day intervals, one of the fan-shaped cut bands, 2-3 inches above the SIJ, and the other below 2-3 inches below the SIJ, and crossed each other by 90 degrees. Both groups were evaluated at baseline and on the 15th day by physical examination of the sacroiliac joint, visual analog scale, Modified Oswestry Pain Inquiry Form. The kinesiological taping group was also evaluated with VAS and positive SIJ pain provocation tests, 20 minutes after the first banding, to assess the acute effect.
PURPOSE:To prevent the discoloration of aloin and to improve the storage stability of an aloe extract containing aloin effective to whiten the skin, by adding a specific acid and dibutylhydroxytoluene to the extract. CONSTITUTION:Aloe juice or extract containing aloin, or isolated aloin, is mixed with dibutylhydroxytoluene (BHT) and one or more compound selected from citric acid, malonic acid, maleic acid, pyruvic acid and phosphoric acid. The amount of BHT is 0.001-0.5wt% based on the whole composition, and the weight ratio of the acid to BHT is 0.1-10, pref. 1-2. The synergistic effect of the acid and BHT prevents the discoloration of aloin at high temperature and with direct sun light irradiation. The composition thus prepared can be used in various fields such as cosmetics.
Benign hepatic adenomas are associated with oral contraceptive use, although the incidence of these benign tumors is rare in the United States. Indirect calculations have estimated the attributable risk to be in the range of 3.3 cases/100,000 for users, a risk that increases after four or more years of use. Rupture of rare, benign, hepatic adenomas may cause death through intra-abdominal hemorrhage.

Studies from Britain have shown an increased risk of developing hepatocellular carcinoma in long-term (>8 years) oral contraceptive user. However, these cancers are extremely rare in the U.S. and the attributable risk (the excess incidence) of liver cancers in oral contraceptive users approaches less than one per million users.

###  RISK OF LIVER ENZYME ELEVATIONS WITH CONCOMITANT HEPATITIS C TREATMENT 

During clinical trials with the Hepatitis C combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN), including some cases greater than 20 times the ULN, were significantly more frequent in women using ethinyl estradiol-containing medications such as COCs. Discontinue levonorgestrel and ethinyl estradiol prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir [see Contraindications (4)]. Levonorgestrel and ethinyl estradiol can be restarted approximately 2 weeks following completion of treatment with the combination drug regimen.
The invention relates to a novel fluorescent probe for detecting apoptosis as well as a preparation method and application thereof, belonging to the field of small molecular marker probes for fluorescence imaging. The fluorescent probe has larger Stokes displacement, and can avoid the interference of some biological autofluorescence; the fluorescent probe can not penetrate through the cell membrane of a living cell, but can penetrate through the cell membrane of an apoptotic cell to be combined with negative charge substances in the cell, has the advantages of obvious fluorescence in cytoplasm or cell nucleus and the like, and can be widely used for selective detection research of the apoptotic cell. The probe can be selectively combined with ATP, DNA or RNA, and can generate large fluorescence enhancement, and can be used for fluorescence detection of the substances. The probe has higher photosensitivity, and can be widely applied to generate ROS under illumination to induce apoptosis of cells or inhibit bacterial growth. The probes have abundant charges and have the potential for membrane potential monitoring. The fluorescent probe also has the advantages of small volume, high labeling specificity, simple and convenient preparation, easy quality control and wide popularization.
PROBLEM TO BE SOLVED: To obtain a food compsn. which has decreased side effects, is effectual, is easy to drink or take in and is capable of decreasing the various symptoms of liver disease patients by incorporating a specific ratio of raffinose into the compsn. SOLUTION: The raffinose is incorporated at least at 1wt.% and more preferably 3 to 15wt.% into the compsn. The raffinose-contg. oligosaccharide mixture produced as a soybean oligosaccharide in addition to the raffinose obtd. from beet roots, soybean whey, etc., may be compounded with the compsn. at the weight corresponding to the desired raffinose content.
OBJECTIVES: I. Determine the maximum tolerated dose and dose limiting toxicity of gemcitabine used in combination with cisplatin in the treatment of squamous cell carcinoma of the head and neck. II. Determine the toxicity profile of this combination treatment in these patients. III. Assess the response rate of treatment in these patients.

OUTLINE: This is a dose escalation study of gemcitabine. Patients receive gemcitabine as an IV bolus on day 1 every 2 weeks. Cisplatin is administered on day 1 every 2 weeks. In the absence of dose limiting toxicity (DLT) in the first 3 patients treated, subsequent cohorts of 3 patients each receive escalating doses of gemcitabine on the same schedule. If 1 of 3 patients in each cohort experiences DLT, an additional 3 patients are enrolled at that same dose level. If 2 of 3 patients experiences DLT in the cohort, then dose escalation ceases and the next lower dose is declared the maximum tolerated dose. Patients are assessed for response every 2 weeks. Patients may continue treatment for up to 9 months or until disease progression.

PROJECTED ACCRUAL: At least 3 patients will be accrued for phase I and 20-40 patients will be accrued for phase II of this study.
PURPOSE:To obtain a narcotic sedative agent by using a specific steroid saponin or its salt originated from starfish. CONSTITUTION:The narcotic and sedative agent containing the steroid saponin of formula I (R<1> is group of formula II, -COCH3, etc.; R<2> is H or SO3H; R<3> is H, group of formula III, etc.) or its salt as an active component. The steroid saponin of formula I can be prepared by purifing the extract of e.g. Asterias amuransis, Acantaster planci, etc. It has been found newly that the compound has narcotic and sedative activity, and is useful as a narcotic sedative agent. The activity is dependent to the dose, and the agent is applied at a dose of 0.1- 3g/day for narcotic by oral administration, and 30mg-1.5g/day for sedative by oral administration.